swelling in the left breast; pain in the left breast; this is a spontaneous report received from a contactable reporter (consumer or other non hcp) from the regulatory authority (ra). a 48 year-old female patient (not pregnant) received bnt162b2 (bnt162b2), administration date 25may2021 (lot number: et8885) as dose 1, single and administration date 26jun2021 (lot number: fa1027) as dose 2, single for covid-19 immunisation. relevant medical history included: "swelling" (unspecified if ongoing); "immunodeficiency" (unspecified if ongoing), notes: has an illness or condition, not listed above, which reduces the immune response (e.g. immunodeficiency). patient had not tested positive for covid-19 since having the vaccine, was not enrolled in clinical trial, was not breastfeeding. the patient's concomitant medications were not reported. the following information was reported: breast swelling (hospitalization) with onset 2021, outcome "recovered" (2021), described as "swelling in the left breast"; breast pain (hospitalization) with onset 2021, outcome "recovered" (2021), described as "pain in the left breast". clinical course: first vaccine caused swelling and pain in the left breast. the report did not relate to possible inflammation of the heart (myocarditis or pericarditis). none of the relevant investigations or tests were conducted. no follow-up attempts are possible. no further information is expected.; sender's comments: linked report(s) : -pfizer inc-202200298715 same patient, same product, different event (dose 3);-pfizer inc-202200347388 same patient, same product, different event